tbuckley/cabot-search huggingface dataset:
Myeloid-Specific JAK2 Contributes to Inflammation and Salt Sensitivity of Blood Pressure
Authors: Mohammad Saleem, Luul A. Aden, Ashley Pitzer Mutchler, Chitra Basu, Lale A. Ertuglu, Quanhu Sheng, Niki Penner, Anna R. Hemnes, Jennifer H. Park, Jeanne A. Ishimwe, Cheryl L. Laffer, Fernando Elijovich, Celestine N. Wanjalla, Nestor de la Visitacion, Paul D. Kastner, Claude F. Albritton, Taseer Ahmad, Alexandria P. Haynes, Justin Yu, Meghan K. Graber, Sharia Yasmin, Kay-Uwe Wagner, Peter P. Sayeski, Antonis K. Hatzopoulos, Eric R. Gamazon, Alexander G. Bick, Thomas R. Kleyman, Annet Kirabo
Journal: Circulation Research (2024)

BACKGROUND: Salt sensitivity of blood pressure (SSBP), characterized by acute changes in blood pressure with changes in dietary sodium intake, is an independent risk factor for cardiovascular disease and mortality in people with and without hypertension. We previously found that elevated sodium concentration activates antigen-presenting cells (APCs), resulting in high blood pressure, but the mechanisms are unknown. Here, we hypothesized that APC-specific JAK2 (Janus kinase 2) through STAT3 (signal transducer and activator of transcription 3) and SMAD3 (small mothers against decapentaplegic homolog 3) contributes to SSBP. METHOD: We performed bulk or single-cell transcriptomic analyses following in vitro monocytes exposed to high salt and in vivo high sodium treatment in humans using a rigorous salt-loading/depletion protocol to phenotype SSBP. We also used a myeloid cell-specific CD11c + JAK2 knockout mouse model and measured blood pressure with radiotelemetry after N-omega-nitro-L-arginine-methyl ester and a high salt diet treatment. We used flow cytometry for immunophenotyping and measuring cytokine levels. Fluorescence in situ hybridization and immunohistochemistry were performed to spatially visualize the kidney’s immune cells and cytokine levels. Echocardiography was performed to assess cardiac function. RESULTS: We found that high salt treatment upregulates gene expression of the JAK/STAT/SMAD pathway while downregulating inhibitors of this pathway, such as suppression of cytokine signaling and cytokine-inducible SH2, in human monocytes. Expression of the JAK2 pathway genes mirrored changes in blood pressure after salt loading and depletion in salt-sensitive but not salt-resistant humans. Ablation of JAK2, specifically in CD11c + APCs, attenuated salt-induced hypertension in mice with SSBP. Mechanistically, we found that SMAD3 acted downstream of JAK2 and STAT3, leading to increased production of highly reactive isolevuglandins and proinflammatory cytokine IL (interleukin)-6 in renal APCs, which activate T cells and increase production of IL-17A, IL-6, and TNF-α (tumor necrosis factor-alpha). CONCLUSIONS: Our findings reveal the APC JAK2 signaling pathway as a potential target for the diagnosis and treatment of SSBP in humans.
Fc-empowered exosomes with superior epithelial layer transmission and lung distribution ability for pulmonary vaccination
Authors: Fan Meng, Haonan Xing, Jingru Li, Yingqi Liu, Li Tang, Zehong Chen, Xiran Jia, Zenglin Yin, Jing Yi, Mei Lu, Xiuli Gao, Aiping Zheng
Journal: Bioactive Materials (2024)
USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression
Authors: Bo Liu, Xianli Zhang, Yuanyuan Zhou, Haiping Liu, Zhenkun Wang, Yuting Fu, Qiongdan Gao, Xiang Cheng, Qingyuan Sun, Zhenyu Ju
Journal: Leukemia (2024)
Correction: Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA
Authors: Min Kang, Bo Tang, Jixi Li, Ziyan Zhou, Kang Liu, Rensheng Wang, Ziyan Jiang, Fangfang Bi, David Patrick, Dongin Kim, Anirban K Mitra, Yang Yang-Hartwich
Journal: Molecular Cancer (2024)
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma
Authors: Carolien C H M Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E Issa, Eduardus F M Posthuma, Josée M Zijlstra, Martine E D Chamuleau, Pieternella J Lugtenburg, Marie José Kersten, Avinash G Dinmohamed
Journal: Blood Cancer Journal (2024)

First-line treatment for advanced-stage diffuse large B-cell lymphoma (DLBCL) typically involves 6x R-CHOP21 or 6x R-CHOP21 with two additional rituximab administrations (6x R-CHOP21 + 2 R). In contemporary practice, this treatment choice might be guided by interim PET scan results. This nationwide, population-based study investigates the comparative effectiveness of these treatment regimens in an era where interim PET-guided treatment decisions were not standard practice. Utilizing the Netherlands Cancer Registry, we identified 1577 adult patients diagnosed with advanced-stage DLBCL between 2014-2018 who completed either 6x R-CHOP21 (43%) or 6x R-CHOP21 + 2 R (57%). We used propensity scores to assess differences in event-free survival (EFS) and overall survival (OS). At five years, EFS (hazard ratio of 6x R-CHOP21 + 2 R versus 6x R-CHOP21 [HR] = 0.89; 95% confidence interval [CI], 0.72-1.09) and OS (HR = 0.93; 95% CI, 0.73-1.18) were not significantly different between both regimens. In exploratory risk-stratified analysis according to the International Prognostic Index (IPI), high-IPI patients (i.e., scores of 4-5) benefit most from 6x R-CHOP21 + 2 R (5-year absolute risk difference of EFS = 16.8%; 95% CI, -0.4%-34.1% and OS = 12.1%; 95% CI, -5.4-29.6%). Collectively, this analysis reveals no significant differences on average in EFS and OS between the two treatments. However, the potential benefits for high-risk patients treated with 6x R-CHOP21 + 2 R underscore the need for future research.
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study
Authors: Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D'Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson
Journal: Leukemia (2024)
Real-World Effectiveness of Menopausal Hormone Therapy in Preventing Relapse in Women With Schizophrenia or Schizoaffective Disorder
Authors: Bodyl A. Brand, Iris E. Sommer, Shiral S. Gangadin, Antti Tanskanen, Jari Tiihonen, Heidi Taipale
Journal: American Journal of Psychiatry (2024)

Antipsychotic effectiveness in preventing relapse declines around menopausal age in women with schizophrenia or schizoaffective disorder (SSD). It is not known whether systemic menopausal hormone therapy (MHT) can help to prevent psychosis relapse.
Autoimmune bullous diseases induced by cyclin-dependent kinase 4/6 inhibitors—first cohort from the EADV Task Force ‘Dermatology for Cancer Patients’
Authors: A Ortiz-Brugués, M Starace, F Bardazzi, D Koumaki, Z Apalla, M Iorizzo, C Bost, E Tournier, S Milesi, J L Lacaze, K Peris, P Sollena, V Sibaud
Journal: Annals of Oncology (2024)
High Burden of Ileus and Pneumonia in Clozapine-Treated Individuals With Schizophrenia: A Finnish 25-Year Follow-Up Register Study
Authors: Juulia J. Partanen, Paavo Häppölä, Anders Kämpe, Ari Ahola-Olli, Anni Hellsten, Susanna M. Rask, Willehard Haaki, Jarmo Hietala, Olli Kampman, Jari Tiihonen, Antti J. Tanskanen, Mark J. Daly, Samuli Ripatti, Aarno Palotie, Heidi Taipale, Markku Lähteenvuo, Jukka T. Koskela
Journal: American Journal of Psychiatry (2024)

The authors used longitudinal biobank data with up to 25 years of follow-up on over 2,600 clozapine users to derive reliable estimates of the real-world burden of clozapine adverse drug events (ADEs).
Risk of Incident Psychosis and Mania With Prescription Amphetamines
Authors: Lauren V. Moran, Joseph P. Skinner, Ann K. Shinn, Kathryn Nielsen, Vinod Rao, S. Trevor Taylor, Talia R. Cohen, Cemre Erkol, Jaisal Merchant, Christin A. Mujica, Roy H. Perlis, Dost Ongur
Journal: American Journal of Psychiatry (2024)

Amphetamine prescribing has increased in the United States in recent years. Previous research identified an increased risk of incident psychosis with prescription amphetamines. The purpose of this study was to examine the impact of dose levels of prescription amphetamines on the risk of this rare but serious adverse outcome.
Closed-Loop Theranostic Microgels for Immune Microenvironment Modulation and Microbiota Remodeling in Ulcerative Colitis
Authors: Zeyuan Jin, Yaqi Zhang, Haijun Hu, Qian Li, Liwen Zhang, Kefei Zhao, Wenxing Liu, Lanjuan Li, Changyou Gao
Journal: Biomaterials (2024)
Severe periodontitis and congenital cytomegalovirus: Cleft lip and cleft palate
Authors: Jørgen Slots, Vanessa Slots
Journal: Periodontology 2000 (2024)

Abstract Severe periodontitis lesions can harbor several hundred‐thousand copies of active cytomegalovirus, and this paper proposes that cytomegalovirus in maternal periodontitis can infect the fetus. Cleft lips and palates may be oral examples of congenital cytomegalovirus infection. Anti‐cytomegalovirus periodontal treatment is indicated for high‐risk women who exhibit severe periodontitis and weakened immune system and are contemplating pregnancy or are in the first trimester of pregnancy.
A just world on a safe planet: a Lancet Planetary Health–Earth Commission report on Earth-system boundaries, translations, and transformations
Authors: Joyeeta Gupta, Xuemei Bai, Diana M Liverman, Johan Rockström, Dahe Qin, Ben Stewart-Koster, Juan C Rocha, Lisa Jacobson, Jesse F Abrams, Lauren S Andersen, David I Armstrong McKay, Govindasamy Bala, Stuart E Bunn, Daniel Ciobanu, Fabrice DeClerck, Kristie L Ebi, Lauren Gifford, Christopher Gordon, Syezlin Hasan, Norichika Kanie, Timothy M Lenton, Sina Loriani, Awaz Mohamed, Nebojsa Nakicenovic, David Obura, Daniel Ospina, Klaudia Prodani, Crelis Rammelt, Boris Sakschewski, Joeri Scholtens, Thejna Tharammal, Detlef van Vuuren, Peter H Verburg, Ricarda Winkelmann, Caroline Zimm, Elena Bennett, Anders Bjørn, Stefan Bringezu, Wendy J Broadgate, Harriet Bulkeley, Beatrice Crona, Pamela A Green, Holger Hoff, Lei Huang, Margot Hurlbert, Cristina Y A Inoue, Şiir Kılkış, Steven J Lade, Jianguo Liu, Imran Nadeem, Christopher Ndehedehe, Chukwumerije Okereke, Ilona M Otto, Simona Pedde, Laura Pereira, Lena Schulte-Uebbing, J David Tàbara, Wim de Vries, Gail Whiteman, Cunde Xiao, Xinwu Xu, Noelia Zafra-Calvo, Xin Zhang, Paola Fezzigna, Giuliana Gentile
Journal: The Lancet Planetary Health (2024)
Organ preservation after neoadjuvant long-course chemoradiotherapy versus short-course radiotherapy
Authors: A Bercz, B K Park, E Pappou, D Nemirovsky, R Sarkar, M Yamner, D Omer, F Verheij, J Alvarez, P Atri, M Reyngold, R Yaeger, I H Wei, A Wu, N Raj, M Widmar, C Hajj, M J Kim, D Rao, G M Nash, V Williams, J Shia, N H Segal, L Diaz, K Ganesh, M R Weiser, M J Gollub, P B Paty, N Horvat, M Zinovoy, D Roth O'Brien, F Sanchez-Vega, L B Saltz, C H Crane, A Cercek, M Gonen, J Garcia-Aguilar, J J Smith, P B Romesser
Journal: Annals of Oncology (2024)
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study
Authors: Timothy W Russell, Hermaleigh Townsley, Joel Hellewell, Joshua Gahir, Marianne Shawe-Taylor, David Greenwood, David Hodgson, Agnieszka Hobbs, Giulia Dowgier, Rebecca Penn, Theo Sanderson, Phoebe Stevenson-Leggett, James Bazire, Ruth Harvey, Ashley S Fowler, Murad Miah, Callie Smith, Mauro Miranda, Philip Bawumia, Harriet V Mears, Lorin Adams, Emine Hatipoglu, Nicola O'Reilly, Scott Warchal, Karen Ambrose, Amy Strange, Gavin Kelly, Svend Kjar, Padmasayee Papineni, Tumena Corrah, Richard Gilson, Vincenzo Libri, George Kassiotis, Steve Gamblin, Nicola S Lewis, Bryan Williams, Charles Swanton, Sonia Gandhi, Rupert Beale, Mary Y Wu, David L V Bauer, Edward J Carr, Emma C Wall, Adam J Kucharski
Journal: The Lancet Infectious Diseases (2024)
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
Authors: Zikun Peng, Huayi Li, Yunong Gao, Li Sun, Jie Jiang, Bairong Xia, Yi Huang, Yu Zhang, Yu Xia, Yuxin Zhang, Yiyang Shen, Bowen Huang, Jiayu Nie, Xinrong Chen, Xingyu Liu, Cui Feng, Zhen Li, Wei Zhang, Kangjia Tao, Qiuxue Zhang, Shican Duan, Yaheng Chen, Yeshan Chen, Wei Wang, Hong Zheng, Yudong Lu, Yi Liu, Limei Wang, Wencai Qi, Yang He, Yan Tian, Guiling Li, Ding Ma, Qinglei Gao
Journal: The Lancet Oncology (2024)
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
Authors: Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Stephanie Pierre, Gina M Scurti, Long Chen, Muna Igboko, Rosa Nadal, Gang Zeng, Gordon Parry, David F Stroncek, Steven Highfill, Annika V Dalheim, Robert Reger, Michael I Nishimura, Richard W Childs
Journal: Journal for ImmunoTherapy of Cancer (2024)

Background We discovered a novel human endogenous retrovirus (CT-RCC HERV-E) that was selectively expressed in most clear cell renal cell carcinomas (ccRCC) and served as a source of antigens for T cell-mediated killing. Here, we described the cloning of a novel T cell receptor (TCR) targeting a CT-RCC HERV-E-derived antigen specific to ccRCC and characterized antitumor activity of HERV-E TCR-transduced T cells (HERV-E T cells). Methods We isolated a CD8 + T cell clone from a patient with immune-mediated regression of ccRCC post-allogeneic stem cell transplant that recognized the CT-RCC-1 HERV-E-derived peptide in an HLA-A11-restricted manner. We used 5’Rapid Amplification of cDNA Ends (RACE) to clone the full length HERV-E TCR and generated retrovirus encoding this TCR for transduction of T cells. We characterized HERV-E T cells for phenotype and function in vitro and in a murine xenograft model. Lastly, we implemented a good manufacturing practice-compliant method for scalable production of HERV-E T cells. Results The HLA-A11-restricted HERV-E-reactive TCR exhibited a CD8-dependent phenotype and demonstrated specific recognition of the CT-RCC-1 peptide. CD8 + T cells modified to express HERV-E TCR displayed potent antitumor activity against HLA-A11 + ccRCC cells expressing CT-RCC HERV-E compared with unmodified T cells. Killing by HERV-E T cells was lost when cocultured against HERV-E knockout ccRCC cells. HERV-E T cells induced regression of established ccRCC tumors in a murine model and improved survival of tumor-bearing mice. Large-scale production of HERV-E T cells under good manufacturing practice conditions generated from healthy donors retained specific antigen recognition and cytotoxicity against ccRCC. Conclusions This is the first report showing that human ccRCC cells can be selectively recognized and killed by TCR-engineered T cells targeting a HERV-derived antigen. These preclinical findings provided the foundation for evaluating HERV-E TCR-transduced T cell infusions in patients with metastatic ccRCC in a clinical trial ( NCT03354390 ).
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD
Authors: Giorgos Bamias, Paola Menghini, Theresa T Pizarro, Fabio Cominelli
Journal: Gut (2024)

TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated cytokine system. The significance of TL1A:DR3 signalling in the pathogenesis of inflammatory bowel disease (IBD) is supported by several converging lines of evidence.To provide a comprehensive understanding of what is currently known regarding the TL1A/DR3 system in the context of IBD.TL1A and DR3 are expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector immune responses, indicating their participation in the pathogenesis of IBD. Recent evidence also supports a homoeostatic role for TL1A:DR3 via regulation of Tregs and innate lymphoid cells. TL1A and DR3 are also expressed by stromal cells and may contribute to inflammation-induced or inflammation-independent intestinal fibrogenesis. Finally, discovery of genetic polymorphisms with functional consequences may allow for patient stratification, including differential responses to TL1A-targeted therapeutics.TL1A:DR3 signalling plays a central and multifaceted role in the immunological pathways that underlie intestinal inflammation, such as that observed in IBD. Such evidence provides the foundation for developing pharmaceutical approaches targeting this ligand-receptor pair in IBD.
S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling
Authors: Feyza Gül Özbay Kurt, Beatrice-Ana Cicortas, Bianca M Balzasch, Carolina De la Torre, Volker Ast, Ece Tavukcuoglu, Cagla Ak, Sebastian A Wohlfeil, Adelheid Cerwenka, Jochen Utikal, Viktor Umansky
Journal: Journal for ImmunoTherapy of Cancer (2024)

Immunotherapies for malignant melanoma are challenged by the resistance developed in a significant proportion of patients. Myeloid-derived suppressor cells (MDSC), with their ability to inhibit antitumor T-cell responses, are a major contributor to immunosuppression and resistance to immune checkpoint therapies in melanoma. Damage-associated molecular patterns S100A8, S100A9, and HMGB1, acting as toll like receptor 4 (TLR4) and receptor for advanced glycation endproducts (RAGE) ligands, are highly expressed in the tumor microenvironment and drive MDSC activation. However, the role of TLR4 and RAGE signaling in the acquisition of MDSC immunosuppressive properties remains to be better defined. Our study investigates how the signaling via TLR4 and RAGE as well as their ligands S100A9 and HMGB1, shape MDSC-mediated immunosuppression in melanoma.
Effect of laughter exercise versus 0.1% sodium hyaluronic acid on ocular surface discomfort in dry eye disease: non-inferiority randomised controlled trial
Authors: Jing Li, Yinglin Liao, Shi-Yao Zhang, Ling Jin, Nathan Congdon, Zixin Fan, Yangfa Zeng, Yingfeng Zheng, Zuguo Liu, Yizhi Liu, Lingyi Liang
Journal: BMJ (2024)

To assess efficacy and safety of laughter exercise in patients with symptomatic dry eye disease.
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma
Authors: Jasmin Elurbide, Leticia Colyn, Maria U Latasa, Iker Uriarte, Stefano Mariani, Amaya Lopez-Pascual, Emiliana Valbuena, Borja Castello-Uribe, Robert Arnes-Benito, Elena Adan-Villaescusa, Luz A Martinez-Perez, Mikel Azkargorta, Felix Elortza, Hanghang Wu, Marcin Krawczyk, Kai Markus Schneider, Bruno Sangro, Luca Aldrighetti, Francesca Ratti, Andrea Casadei Gardini, Jose J G Marin, Irene Amat, Jesus M Urman, Maria Arechederra, Maria Luz Martinez-Chantar, Christian Trautwein, Meritxell Huch, Francisco Javier Cubero, Carmen Berasain, Maite G Fernandez-Barrena, Matias A Avila
Journal: Gut (2024)

Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified.
Endothelial estrogen - myocardial cGMP axis critically determines angiogenesis and cardiac performance during pressure-overload
Authors: Nobuaki Fukuma, Hiroyuki Tokiwa, Genri Numata, Kazutaka Ueda, Pang-Yen Liu, Miyu Tajima, Yu Otsu, Taro Kariya, Yukio Hiroi, James K Liao, Issei Komuro, Eiki Takimoto
Journal: Cardiovascular Research (2024)

Oestrogen exerts beneficial cardiovascular effects by binding to specific receptors on various cells to activate nuclear and non-nuclear actions. Oestrogen receptor α (ERα) non-nuclear signalling confers protection against heart failure remodelling, involving myocardial cyclic guanosine monophosphate (cGMP)-cGMP-dependent protein kinase G (PKG) activation; however, its tissue-specific role remains elusive. Herein, we examine the cell type-specific role of ERα non-nuclear signalling in oestrogen-conferred protection against heart failure.
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies
Authors: John Stagg, J. Silvio Gutkind
Journal: The Annual Review of Pharmacology and Toxicology (2024)

The advent of cancer immunotherapy based on PD-1 and CTLA-4 immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many cancers do not respond to ICB, highlighting the urgent need for additional approaches to achieve durable cancer remission. The large family of G protein–coupled receptors (GPCRs) is the target of more than 30% of all approved drugs, but GPCRs have been underexploited in cancer immunotherapy. In this review, we discuss the central role of GPCRs in immune cell migration and function and describe how single-cell transcriptomic studies are illuminating the complexity of the human tumor immune GPCRome. These receptors include multiple GPCRs expressed in CD8 T cells that are activated by inflammatory mediators, protons, neurotransmitters, and metabolites that accumulate in the tumor microenvironment, thereby promoting T cell dysfunction. We also discuss new opportunities to target GPCRs as a multimodal approach to enhance the response to ICB for a myriad of human malignancies.
Advancements in Assays for Micro- and Nanoplastic Detection: Paving the Way for Biomonitoring and Exposomics Studies
Authors: Kuanliang Shao, Runyu Zou, Zhuoyue Zhang, Laurens D.B. Mandemaker, Sarah Timbie, Ronald D. Smith, Amanda M. Durkin, Hanna M. Dusza, Florian Meirer, Bert M. Weckhuysen, Tanya L. Alderete, Roel Vermuelen, Douglas I. Walker
Journal: The Annual Review of Pharmacology and Toxicology (2024)

Although plastic pollution and exposure to plastic-related compounds have received worldwide attention, health risks associated with micro- and nanoplastics (MNPs) are largely unknown. Emerging evidence suggests MNPs are present in human biofluids and tissue, including blood, breast milk, stool, lung tissue, and placenta; however, exposure assessment is limited and the extent of human exposure to MNPs is not well known. While there is a critical need to establish robust and scalable biomonitoring strategies to assess human exposure to MNPs and plastic-related chemicals, over 10,000 chemicals have been linked to plastic manufacturing with no existing standardized approaches to account for even a fraction of these exposures. This review provides an overview of the status of methods for measuring MNPs and associated plastic-related chemicals in humans, with a focus on approaches that could be adapted for population-wide biomonitoring and integration with biological response measures to develop hypotheses on potential health effects of plastic exposures. We also examine the exposure risks associated with the widespread use of chemical additives in plastics. Despite advancements in analytical techniques, there remains a pressing need for standardized measurement protocols and untargeted, high-throughput analysis methods to enable comprehensive MNP biomonitoring to identify key MNP exposures in human populations. This review aims to merge insights into the toxicological effects of MNPs and plastic additives with an evaluation of analytical challenges, advocating for enhanced research methods to fully assess, understand, and mitigate the public health implications of MNPs.
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study
Authors: Sam Nightingale, Anna J Dreyer, Kevin G F Thomas, Gert van Zyl, Eric Decloedt, Petrus J W Naude, Catherine Orrell, Phumla Sinxadi, Alan Winston, Saye Khoo, John A Joska
Journal: The Lancet HIV (2024)
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
Authors: Othon Iliopoulos, Ane B Iversen, Vivek Narayan, Benjamin L Maughan, Kathryn E Beckermann, Stephane Oudard, Tobias Else, Jodi K Maranchie, Cynthia Muller Goldberg, Wei Fu, Rodolfo F Perini, Yanfang Liu, W Marston Linehan, Ramaprasad Srinivasan, Eric Jonasch
Journal: The Lancet Oncology (2024)